Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments

Introduction Cancer patients are at risk for serious complications in case of SARS-CoV-2 infection. In these patients SARS-CoV-2 vaccination is strongly recommended, with the preferential use of mRNA vaccines. The antibody response in cancer patients is variable, depending on the type of cancer and antitumoral treatment. In solid tumor patients an antibody response similar to healthy subjects has been confirmed after the second dose. Only few studies explored the duration of immunization after the two doses and the effect of the third dose. Methods In our study we explored a cohort of 273 solid tumor patients at different stages and treated with different anticancer therapies. Results and Discussion Our analysis demonstrated that the persistence of the neutralizing antibody and the humoral response after the booster dose of vaccine was not dependent on either the tumor type, the stage or type of anticancer treatment.

[1]  M. Fernández-arquero,et al.  Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients , 2022, Frontiers in Oncology.

[2]  C. Riccardi,et al.  Immune correlates of protection by vaccine against SARS‐CoV‐2 in patients with chronic lymphocytic leukaemia , 2022, British journal of haematology.

[3]  M. M.,et al.  Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia. , 2022, Hematological oncology.

[4]  O. Levy,et al.  Immunogenicity of a Three-Dose Primary Series of mRNA COVID-19 Vaccines in Patients With Lymphoid Malignancies , 2022, Open forum infectious diseases.

[5]  Shuo Ma,et al.  CLO22-043: Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Large, Single-Center Observational Study , 2022, Journal of the National Comprehensive Cancer Network.

[6]  M. Dieci,et al.  Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020–Sep 2020; Sep 2020–May 2021) in the Veneto Oncology Network: The ROVID study , 2022, European Journal of Cancer.

[7]  C. Castilletti,et al.  Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up , 2022, Viruses.

[8]  L. Pickering,et al.  Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer , 2021, Cancer Cell.

[9]  G. Rahav,et al.  Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination , 2021, Blood.

[10]  G. Pessina,et al.  Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study , 2021, Annals of Oncology.

[11]  L. Kadouri,et al.  Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment. , 2021, JAMA oncology.

[12]  K. Pradhan,et al.  Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer , 2021, Cancer Cell.

[13]  M. Koopmans,et al.  mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial , 2021, The Lancet Oncology.

[14]  B. LaFleur,et al.  Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors , 2021, Nature Medicine.

[15]  M. Preusser,et al.  Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations. , 2021, JAMA oncology.

[16]  Patrick W. Johnson,et al.  Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies , 2021, Cancer Cell.

[17]  A. Reiner-Benaim,et al.  Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors. , 2021, Cancer discovery.

[18]  Z. Čermáková,et al.  1563MO CoVigi phase IV multicentric trial evaluating COVID-19 vaccination adverse events and immune response dynamics in cancer patients: First results on antibody and cellular immunity , 2021, Annals of Oncology.

[19]  I. Waldhorn,et al.  1559O Efficacy and toxicity of BNT162b2 vaccine in cancer patients , 2021, Annals of Oncology.

[20]  C. Swanton,et al.  1557O Adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients: The CAPTURE study , 2021, Annals of Oncology.

[21]  G. Tomlinson,et al.  Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients , 2021, The New England journal of medicine.

[22]  K. Pradhan,et al.  Seroconversion rates following COVID-19 vaccination among patients with cancer , 2021, Cancer Cell.

[23]  M. Dieci,et al.  Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study , 2021, European journal of cancer.

[24]  M. Dieci,et al.  Epidemiology and clinical course of SARS-CoV-2 infection in cancer patients in the Veneto Oncology Network: The ROVID Study , 2021, European Journal of Cancer.

[25]  T. Mann,et al.  6-Month Follow-Up , 2016 .

[26]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[27]  J. Cooper.  Ajcc Cancer Staging Manual , 1997 .